Belgian Start-up UgenTec Receives Funding from European Investors
UgenTec, a start-up company based in Belgium that develops laboratory software for automating PCR based DNA analysis, announced that it has received more than €1m in venture capital funding from a group of Belgian investors and an additional €250,000 in research funds from the IWT, a government agency for Innovation by Science and Technology. The investors include former MedHold (now part of Sonic Healthcare) CEO Annie Vereecken, Cartagenia CEO Herman Verrelst and a KULeuven investment group led by prof. Bart De Moor. LRM, a Belgian investment company will also support UgenTec with a loan of €100,000.
UgenTec will use the new funds for software development, international expansion including preparation for commercialization in the U.S. and recruitment, noted Wouter Uten, CEO of UgenTec.
Other news from the department business & finance

Get the analytics and lab tech industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.